Pharma major Sun Pharmaceutical Industries Limited has announced the appointment of Kirti Ganorkar as Managing Director, effective September 1, 2025.
He is succeeding founder Dilip Shanghvi. The appointment is subject to shareholder approval at the company’s upcoming Annual General Meeting.
In his new role, all business verticals and functions will report to Ganorkar, signalling a seamless transition of operational leadership.
Dilip Shanghvi to Continue as Executive Chairman
Dilip Shanghvi, who founded Sun Pharma and led it to become one of the world’s largest pharmaceutical companies, will continue as Executive Chairman.
He will chair the Board, focus on strengthening the company’s specialty portfolio, and provide strategic guidance for long-term growth.
The leadership shift marks the culmination of a carefully planned succession strategy, ensuring continuity of values and vision.
Ganorkar’s Career and Contributions
Ganorkar has been with Sun Pharma since 1996, bringing nearly three decades of rich and diverse experience.
He has held key leadership positions in business development, marketing, mergers and acquisitions (M&A), project management, intellectual property, litigation, and new product launches.
Since June 2019, he has successfully led Sun Pharma’s India Business, delivering consistent growth and enhanced market share.
He played a pivotal role in acquiring global rights for the specialty product Ilumya, led the company’s entry into Japan, and laid the groundwork for expansion in Europe.
Additionally, he supported several strategic generic launches in the U.S. A chemical engineer and MBA, Ganorkar is recognized for combining strategic vision with execution excellence.
Leadership Reflections
Kirti Ganorkar expressed his enthusiasm for the new role, stating, “Sun Pharma is at an exciting juncture, with all businesses well-positioned for growth. Building on the strong foundation laid by Mr. Shanghvi and supported by our global leadership team, I’m confident of continued success.”
Dilip Shanghvi added, “Kirti has demonstrated strong leadership across multiple functions. I believe in his ability to take Sun Pharma into its next growth phase. His elevation highlights our internal talent strength and ensures leadership continuity.”
A Strategic Step Forward
The leadership transition underscores Sun Pharma’s focus on succession planning, global expansion, and long-term value creation, particularly across regulated markets such as the U.S., Japan, and Europe.
Note: We are also on WhatsApp, LinkedIn, Google News, and YouTube, to get the latest news updates. Subscribe to our Channels. WhatsApp– Click Here, YouTube– Click Here, and LinkedIn– Click Here.
